QIAGEN Receives Approval for EGFR Test in Lung Cancer as Companion Diagnostic in Japan
January 17, 2019 at 02:30 am IST
QIAGEN N.V. announced that the Japanese Pharmaceuticals and Medical Device Agency (PMDA) has approved the therascreen® EGFR RGQ PCR Kit to allow its use as a companion diagnostic with Pfizer’s VIZIMPRO® (dacomitinib) for EGFR gene mutation-positive, inoperable or recurrent non-small cell lung cancer. The therascreen® EGFR RGQ PCR Kit is registered in more than 40 countries globally. This marks the first companion diagnostic approval for QIAGEN in Japan.